Last checked at 26 Jul 2018 14:19
Publication of GlaxoSmithKline Capital plc
Interim Management Report 2018
Today, 26 July 2018, GlaxoSmithKline Capital plc (the "Company") published on the GlaxoSmithKline Group ("GSK") website, www.gsk.com *, its Interim Management Report in respect of the period ended 30 June 2018.
In compliance with Listing Rule 9.6.1 of the UK Financial Conduct Authority ('FCA'), copies of Company's Interim Management Report, have been submitted to the UK Listing Authority's National Storage Mechanism and will shortly be available for inspection at http:/www.morningstar.co.uk/UK/NSM.
In accordance with the FCA's Disclosure and Transparency Rules 4.2 and 6.3.5, Appendix A to this announcement contains the Company's Interim Management Report, which includes a description of the principal risks and uncertainties affecting it together with a responsibility statement.
V A Whyte
Company Secretary
26 July 2018
* https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/other-reports
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017.
APPENDIX A
| ||||||
| ||||||
GlaxoSmithKline Capital plc | ||||||
(Registered number: 2258699) | ||||||
| ||||||
Interim Management Report | ||||||
| ||||||
for the half year ended 30 June 2018 | ||||||
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Registered office address: | |
|
|
|
|
| 980 Great West Road | |
|
|
|
|
| Brentford | |
|
|
|
|
| Middlesex | |
|
|
|
|
| TW8 9GS | |
GlaxoSmithKline Capital plc | |
(Registered number: 2258699) | |
| |
Interim Management Report | |
| |
for the half year ended 30 June 2018 | |
| |
| |
| |
| |
Contents | Pages |
|
|
Interim report | 1-2 |
|
|
Income statement | 3 |
|
|
Statement of comprehensive income | 4 |
|
|
Statement of financial position | 5 |
|
|
Statement of changes in equity | 6 |
|
|
Cash flow statement | 7 |
|
|
Notes to the financial statements | 8-12 |
|
|
GlaxoSmithKline Capital plc |
Results announcement and interim management report for the half year ended 30 June 2018 |
|
Performance |
|
GlaxoSmithKline Capital plc (the "Company") is a member of the GlaxoSmithKline Group (the "Group"). The principal activities of the Company during the financial year were the issuance of notes under the Group's European Medium Term Note programme and the provision of financial services to other companies within the Group. |
|
The Directors do not envisage any change to the nature of the business in the foreseeable future. |
|
Review of business |
|
The Company made a profit for the half year ended 30 June 2018 of £16,814,000 (2017: £4,055,000), which will be transferred to reserves. The Directors are of the opinion that the current level of activity and the period end financial position are satisfactory and will remain so in the foreseeable future. |
|
No dividend is proposed to the holders of ordinary shares in respect of the period ended 30 June 2018 (2017: £nil). |
|
At 30 June 2018, the Company had in issue £11,224,361,000 European Medium Term Notes and £3,016,815,000 US Medium Term Notes (31 December 2017: £9,026,788,000 and £1,473,973,000, respectively), which mature at dates between 2019 and 2045. All notes currently in issue pay interest on a fixed rate basis, with the exception of the €750 million (£656 million) 2020 European Medium Term Note and $750 million (£554 million) 2021 US Medium Term Note which are on a floating rate basis. |
|
Principal risks and uncertainties |
|
The Directors of GlaxoSmithKline plc manage the risks of the Group at a group level, rather than at an individual statutory entity level. For this reason, the Company's Directors believe that a discussion of the Group's risks would not be appropriate for an understanding of the development, performance or position of the Company's business. The principal risks and uncertainties of the Group, which include those of the Company, are discussed in the Group's 2017 Annual Report which does not form part of this report. |
|
Details of the Company's financial risk management is also disclosed in the Company's Annual Report for the year ended 31 December 2017. |
|
Directors' responsibility statement |
|
The Board of Directors approved this document on 24 July 2018. |
|
The Directors confirm that to the best of their knowledge this unaudited condensed financial information for the six months ended 30 June 2018 has been prepared in accordance with Financial Reporting Standard 104 "Interim Financial Reporting" and that the interim management report herein includes a true and fair view of the information required by Disclosure and Transparency Rules (DTR) 4.2.7. |
|
The Directors of the Company are: |
|
|
Mr S Dingemans |
Edinburgh Pharmaceutical Industries Limited |
Glaxo Group Limited |
|
|
|
|
By order of the Board |
|
|
|
Mr A Walker |
For and on behalf of Glaxo Group Limited |
Corporate Director |
24 July 2018 |
|
|
Internet |
This Announcement and other information about the GSK Group are available on the website at: http://www.gsk.com |
GlaxoSmithKline Capital plc Income statement |
|
|
|
for the half year ended 30 June 2018 |
|
|
|
|
| Period ended | Period ended |
|
| 30 June 2018 | 30 June 2017 |
| Note | £'000 | £'000 |
|
|
|
|
Other operating income / (expense) |
| 214 | (511) |
Finance income | 3 | 172,296 | 196,552 |
Finance expense | 4 | (151,712) | (191,019) |
Operating profit | 2 | 20,798 | 5,022 |
|
|
|
|
Profit before taxation |
| 20,798 | 5,022 |
|
|
|
|
Tax on profit | 5 | (3,984) | (967) |
|
|
|
|
Profit for the financial period |
| 16,814 | 4,055 |
|
|
|
|
GlaxoSmithKline Capital plc Statement of comprehensive income |
|
|
|
for the half year ended 30 June 2018 |
|
|
|
|
| Period ended | Period ended |
|
| 30 June 2018 | 30 June 2017 |
|
| £'000 | £'000 |
|
|
|
|
Profit for the financial period |
| 16,814 | 4,055 |
|
|
|
|
Items that may be subsequently reclassified to the income statement: |
|
| |
Fair value movements on cash flow hedges |
| 1,288 | - |
Reclassification of cash flow hedges to the income statement |
| 731 | 477 |
Deferred tax on cash flow hedges |
| (124) | (81) |
Other comprehensive income for the financial period |
| 1,895 | 396 |
|
|
|
|
Total comprehensive income for the financial period |
| 18,709 | 4,451 |
GlaxoSmithKline Capital plc Statement of financial position |
|
|
|
As at 30 June 2018 |
|
|
|
|
|
|
|
|
| 30 June 2018 | 31 December 2017 |
| Note | £'000 | £'000 |
|
|
|
|
Non-current assets |
|
|
|
Deferred tax assets |
| 2,249 | 2,373 |
Loans and receivables | 6 | 14,181,660 | 10,434,878 |
Total non-current assets |
| 14,183,909 | 10,437,251 |
|
|
|
|
Current assets |
|
|
|
Loans and receivables | 6 | 107,785 | 101,855 |
Prepayments and accrued income | 7 | 104,516 | 107,833 |
Cash and cash equivalents |
| 1 | 1 |
Total current assets |
| 212,302 | 209,689 |
|
|
|
|
Total assets |
| 14,396,211 | 10,646,940 |
|
|
|
|
Current liabilities |
|
|
|
Other payables | 8 | (5,966) | (4,864) |
Accruals and deferred income | 10 | (92,725) | (103,680) |
Total current liabilities |
| (98,691) | (108,544) |
|
|
|
|
Net current assets |
| 113,611 | 101,145 |
|
|
|
|
Total assets less current liabilities |
| 14,297,520 | 110,538,396 |
|
|
|
|
Non-current liabilities |
|
|
|
Long-term borrowings | 9 | (14,241,176) | (10,500,761) |
Total non-current liabilities |
| (14,241,176) | (10,500,761) |
|
|
|
|
Total liabilities |
| (14,339,867) | (10,609,305) |
|
|
|
|
Net assets |
| 56,344 | 37,635 |
|
|
|
|
Equity |
|
|
|
Called up share capital | 13 | 100 | 100 |
Other reserves |
| (9,693) | (11,588) |
Retained earnings |
| 65,937 | 49,123 |
|
|
|
|
Total equity |
| 56,344 | 37,635 |
|
|
|
|
GlaxoSmithKline Capital plc Statement of changes in equity |
for the half year ended 30 June 2018 |
| Called up share capital | Other reserves | Retained earnings | Total equity |
| £'000 | £'000 | £'000 | £'000 |
|
|
|
|
|
At 1 January 2017 | 100 | (9,243) | 40,805 | 31,662 |
|
|
|
|
|
Profit for the financial period | - | - | 4,055 | 4,055 |
Other comprehensive income for thefinancial period | - | 396 | - | 396 |
|
|
|
|
|
At 30 June 2017 | 100 | (8,847) | 44,860 | 36,113 |
| Called up share capital | Other reserves | Retained earnings | Total equity |
| £'000 | £'000 | £'000 | £'000 |
|
|
|
|
|
At 1 January 2018 | 100 | (11,588) | 49,123 | 37,635 |
|
|
|
|
|
Profit for the financial period | - | - | 16,814 | 16,814 |
Other comprehensive income for thefinancial period | - | 1,895 | - | 1,895 |
|
|
|
|
|
At 30 June 2018 | 100 | (9,693) | 65,937 | 56,344 |
GlaxoSmithKline Capital plc Cash flow statement |
|
|
|
for the half year ended 30 June 2018 |
| ||
|
| Period ended | Period ended |
|
| 30 June 2018 | 30 June 2017 |
| Note | £'000 | £'000 |
|
|
|
|
Cash flows from operating activities |
|
|
|
Operating profit |
| 20,798 | 5,022 |
Adjustments reconciling operating profit to operating cash flows | 12 | (20,852) | (312) |
Net cash (outflow) / inflow from operating activities |
| (54) | 4,710 |
|
|
|
|
Cash flows from financing activities Proceeds from borrowings |
| 3,650,522 | - |
Repayment of borrowings |
| - | (1,543,721) |
Loans provided to Group undertakings |
| (3,648,326) | - |
Loan repayments received from Group undertakings |
| - | 1,532,776 |
(Increase) / decrease in current accounts with Group undertakings |
| (2,142) | 6,235 |
Net cash inflow / (outflow) from financing activities |
| 54 | (4,710) |
|
|
|
|
Net movement in cash in the period |
| - | - |
|
|
|
|
Cash at beginning of period |
| 1 | 2 |
Movement in cash |
| - | - |
|
|
|
|
Cash at end of period |
| 1 | 2 |
| GlaxoSmithKline Capital plc | |||||||||||
| Notes to the financial statements for the half year ended 30 June 2018 | |||||||||||
|
| |||||||||||
1 | Accounting presentation and policies | |||||||||||
|
| |||||||||||
| This unaudited Results Announcement containing condensed financial information for the six months ended 30 June 2018 is prepared in accordance with Financial Reporting Standard 104 "Interim Financial Reporting" using the recognition and measurement requirements of Financial Reporting Standard 101 "Reduced Disclosure Framework" and in accordance with the Listing Rules of the UK Listing Authority. | |||||||||||
| ||||||||||||
2 | Operating profit | |||||||||||
|
|
| Period ended | Period ended | ||||||||
|
|
| 30 June 2018 | 30 June 2017 | ||||||||
|
|
| £'000 | £'000 | ||||||||
|
|
|
|
|
|
| ||||||
| The following items have been credited / (charged) in operating profit: |
|
| |||||||||
| Exchange gains on foreign currency transactions |
|
| 214 | (511) | |||||||
|
| |||||||||||
3 | Finance income | |||||||||||
|
|
|
|
|
| Period ended | Period ended | |||||
|
|
|
|
|
| 30 June 2018 | 30 June 2017 | |||||
|
|
|
|
|
| £'000 | £'000 | |||||
|
|
|
|
|
|
|
| |||||
| Interest income arising from loans with Group undertakings | 172,296 | 196,552 | |||||||||
|
|
|
|
|
|
|
| |||||
4 | Finance expense | |||||||||||
|
|
|
|
|
| Period ended | Period ended | |||||
|
|
|
|
|
| 30 June 2018 | 30 June 2017 | |||||
|
|
|
|
|
| £'000 | £'000 | |||||
|
|
|
|
|
| |||||||
| Interest expense arising on financial liabilities at amortised cost | (150,981) | (190,542) | |||||||||
| Reclassification of cash flow hedge from other comprehensive income | (731) | (477) | |||||||||
|
|
|
|
|
| |||||||
| Total finance expense |
|
| (151,712) | (191,019) | |||||||
|
| |||||||||||
5 | Tax on profit |
|
|
|
|
| ||||||
|
|
|
|
|
| Period ended | Period ended | |||||
|
|
|
|
|
| 30 June 2018 | 30 June 2017 | |||||
| Income tax expense on ordinary activities | £'000 | £'000 | |||||||||
|
|
|
|
|
|
|
| |||||
| Current tax: |
|
|
|
| |||||||
| UK corporation tax at 19.25% (2017: 19.25%) |
|
| (3,984) | (967) | |||||||
|
|
|
|
|
| |||||||
| Total current tax |
|
| (3,984) | (967) | |||||||
| ||||||||||||
6 | Loans and receivables | |||||||||||
|
|
|
|
|
| 30 June 2018 | 31 December 2017 | |||||
|
| £'000 | £'000 | |||||||||
|
|
|
|
|
|
|
| |||||
| Amounts due within one year |
|
|
|
| |||||||
| Amounts owed by Group undertakings - current accounts |
| 107,785 | 101,855 | ||||||||
|
|
|
|
|
| |||||||
|
|
|
| 107,785 | 101,855 | |||||||
|
|
|
|
|
| |||||||
|
|
|
|
|
| |||||||
|
|
|
|
|
| |||||||
|
|
|
|
|
| |||||||
|
|
|
|
|
| |||||||
6 | Loans and receivables (continued) |
|
|
|
| |||||||
|
|
|
| 30 June 2018 | 31 December 2017 | |||||||
|
|
|
| £'000 | £'000 | |||||||
|
|
|
|
|
| |||||||
| Amounts due after more than one year |
|
|
|
| |||||||
| Amounts owed by Group undertakings - loans |
|
| 14,181,660 | 10,434,878 | |||||||
|
|
|
|
|
| |||||||
|
|
|
| 14,181,660 | 10,434,878 | |||||||
|
|
|
|
|
| |||||||
|
|
|
| 14,289,445 | 10,536,733 | |||||||
|
| |||||||||||
| Amounts due within one year are call accounts with Group undertakings of £47,840,000 (2017: £45,025,000) which are unsecured, repayable on demand and earn a market rate of interest (based on 1 week LIBOR minus 0.125%) that is consistent with the Group's policy and includes deposits with Group undertakings of £59,945,000 (2017: £56,830,000) which are unsecured, repayable on demand and earn a market rate of interest (based on LIBOR minus 0.125%) that is consistent with the Group's policy.
| |||||||||||
| Amounts due after more than one year are the net proceeds of bond issuances that have been advanced as loans to Group undertakings, which are unsecured with fixed interest charged between 0.21% and 6.50% per annum and floating interest charged between LIBOR plus 20bps to 56bps and repayable at maturity dates between 2019 and 2045.
| |||||||||||
7 | Prepayments and accrued income | |||||||||||
|
|
|
|
|
| 30 June 2018 | 31 December 2017 | |||||
|
| £'000 | £'000 | |||||||||
|
|
|
|
|
|
|
| |||||
| Amounts due within one year |
|
| 104,516 | 107,833 | |||||||
|
|
|
|
|
| |||||||
| Accrued income relates to interest on amounts owed by Group undertakings (see Note 6). | |||||||||||
|
|
|
|
|
| |||||||
8 | Other payables | |||||||||||
|
|
|
|
|
| 30 June 2018 | 31 December 2017 | |||||
|
| £'000 | £'000 | |||||||||
|
|
|
|
|
|
|
| |||||
| Amounts falling due within one year |
|
|
|
| |||||||
| Amounts owed to Group undertakings |
|
| - | (2,881) | |||||||
| Corporation tax |
| (5,966) | (1,983) | ||||||||
|
|
|
|
|
| |||||||
|
|
|
| (5,966) | (4,864) | |||||||
|
|
|
|
|
| |||||||
| Amounts owed to Group undertakings are unsecured and repayable on demand. | |||||||||||
|
| |||||||||||
| The corporation tax creditor contains amounts which will be paid to fellow Group companies under Group relief. | |||||||||||
|
| |||||||||||
|
| |||||||||||
|
| |||||||||||
|
| |||||||||||
|
| |||||||||||
|
| |||||||||||
|
| |||||||||||
|
| |||||||||||
9 | Borrowings | |||||||||||
|
|
|
|
|
| 30 June 2018 | 31 December 2017 | |||||
|
| £'000 | £'000 | |||||||||
|
|
|
|
|
|
|
| |||||
| Amounts falling due within one year |
|
|
|
| |||||||
| Loans payable: |
|
|
|
| |||||||
| € European Medium Term Notes |
|
| (7,181,696) | (4,973,782) | |||||||
| £ European Medium Term Notes |
|
| (4,042,665 | (4,053,006) | |||||||
| US$ Medium Term Notes |
| (3,016,815) | (1,473,973) | ||||||||
|
|
|
|
|
| |||||||
|
|
|
| (14,241,176) | (10,500,761) | |||||||
|
|
|
|
|
| |||||||
|
|
|
| 30 June 2018 | 31 December 2017 | |||||||
| Maturity of borrowings |
|
| £'000 | £'000 | |||||||
|
|
|
|
|
| |||||||
| In more than one year, but not more than two years |
|
|
|
| |||||||
| 0.625% € European Medium Term Note 2019 |
|
| (1,324,563) | (1,323,623) | |||||||
| LIBOR + 20bps € European Medium Term Note 2020 |
|
| (665,819) | - | |||||||
|
|
|
|
|
| |||||||
|
|
|
| (1,990,382) | (1,323,623) | |||||||
|
|
|
|
|
| |||||||
| In more than two years, but not more than five years |
|
|
| ||||||||
| 0.000% € European Medium Term Note 2020 |
|
| (1,059,826) | (1,059,379) | |||||||
| LIBOR + 35bps US$ US Medium Term Note 2021 |
|
| (566,821) | - | |||||||
| 3.125% US$ Medium Term Note 2021 |
|
| (942,252) | - | |||||||
| 2.850% US$ Medium Term Note 2022 |
|
| (1,507,742) | (1,473,973) | |||||||
|
|
|
|
|
| |||||||
|
|
|
| (4,076,641) | (2,533,352) | |||||||
|
|
|
|
|
| |||||||
| In more than five years |
|
|
|
| |||||||
| 1.375% € European Medium Term Note 2024 |
|
| (876,527) | (876,117) | |||||||
| 4.000% € European Medium Term Note 2025 |
|
| (657,660) | (658,647) | |||||||
| 1.000% € European Medium Term Note 2026 |
|
| (617,292) | (617,178) | |||||||
| 1.350% € European Medium Term Note 2026 |
|
| (880,423) | - | |||||||
| 3.375% £ European Medium Term Note 2027 |
|
| (593,037) | (593,400) | |||||||
| 1.375% € European Medium Term Note 2029 |
|
| (438,964) | (438,838) | |||||||
| 1.750% € European Medium Term Note 2030 |
|
| (660,623) | - | |||||||
| 5.250% £ European Medium Term Note 2033 |
|
| (981,316) | (986,476) | |||||||
| 6.375% £ European Medium Term Note 2039 |
|
| (693,911) | (695,330) | |||||||
| 5.250% £ European Medium Term Note 2042 |
|
| (986,065) | (988,603) | |||||||
| 4.250% £ European Medium Term Note 2045 |
|
| (788,335) | (789,197) | |||||||
|
|
|
|
|
| |||||||
|
|
|
| (8,174,153) | (6,643,786) | |||||||
|
|
|
|
|
| |||||||
| Total borrowings |
|
| (14,241,176) | (10,500,761) | |||||||
|
|
|
|
|
| |||||||
10 | Accruals and deferred income |
|
|
|
| |||||||
|
|
|
| 30 June 2018 | 31 December 2017 | |||||||
|
|
|
| £'000 | £'000 | |||||||
|
|
|
|
|
| |||||||
| Amounts falling due within one year |
|
| (92,725) | (103,680) | |||||||
|
|
|
|
|
| |||||||
| Accruals relates to interest payable on borrowings (see Note 9). |
|
|
| ||||||||
|
| |||||||||||
11 | Fair value of financial assets and liabilities | |||||||||||
|
| |||||||||||
| The fair values of the financial assets and liabilities are included at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. | |||||||||||
|
| |||||||||||
| The following methods and assumptions were used to estimate the fair values: | |||||||||||
|
| |||||||||||
| · | Cash and cash equivalents - approximates to the carrying amount; | ||||||||||
| · | Borrowings (European and US Medium Term Notes) - based on quoted market prices (a level 1 fair value measurement); | ||||||||||
| · | Intercompany loans - approximates to the fair value of borrowings (European and US Medium Term Notes); and | ||||||||||
| · | Receivables and payables - approximates to the carrying amount. | ||||||||||
|
|
| ||||||||||
| The carrying amounts and the fair values of the Company's financial assets and liabilities at 30 June 2018 and 31 December 2017 are illustrated below. | |||||||||||
|
| |||||||||||
|
|
|
| 30 June 2018 | 31 December 2017 | |||||||
|
|
|
| Carrying value | Fair value | Carrying value | Fair value | |||||
|
|
|
| £'000 | £'000 | £'000 | £'000 | |||||
|
|
|
|
|
|
|
| |||||
| Cash and cash equivalents |
| 1 | 1 | 1 | 1 | ||||||
|
|
|
|
|
| |||||||
| Loans and receivables: |
|
|
|
| |||||||
| Other receivables | 104,516 | 104,516 | 107,833 | 107,833 | |||||||
| Amounts owed by Group undertakings - current accounts | 107,785 | 107,785 | 101,855 | 101,855 | |||||||
| Amounts owed by Group undertakings - loans | 14,181,660 | 15,891,483 | 10,434,878 | 12,413,202 | |||||||
|
|
|
|
|
|
|
| |||||
| Total financial assets | 14,393,962 | 16,103,785 | 10,644,567 | 12,622,891 | |||||||
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||||
| Financial liabilities measured at amortised cost: |
|
|
| ||||||||
|
|
|
|
| ||||||||
| £ European Medium Term Notes |
| (4,042,665) | (5,427,306) | (4,053,006) | (5,688,556) | ||||||
| € European Medium Term Notes |
| (7,181,696) | (7,454,757) | (4,973,782) | (5,221,979) | ||||||
| US$ US Medium Term Notes |
| (3,016,815) | (3,009,420) | (1,473,973) | (1,502,667) | ||||||
|
|
|
|
|
|
|
| |||||
|
|
| (14,241,176) | (15,891,483) | (10,500,761) | (12,413,202) | ||||||
|
|
|
|
|
|
| ||||||
| Other payables |
| (92,725) | (92,725) | (106,561) | (106,561) | ||||||
|
|
|
|
|
|
| ||||||
| Total financial liabilities |
| (14,333,901) | (15,984,208) | (10,607,322) | (12,519,763) | ||||||
|
|
|
|
|
| |||||||
| Net financial assets and liabilities | 60,061 | 119,577 | 37,245 | 103,128 | |||||||
|
|
|
|
|
|
| ||||||
| The Company has no financial assets or liabilities measured at fair value through profit or loss. | |||||||||||
|
| |||||||||||
| Financial liabilities measured at amortised cost for which the fair value of £15,891,483,000 (31 December 2017: £12,413,202,000) as disclosed in the table above are categorised as Level 1, where quoted prices in active markets are used. Similarly, amounts owed by Group undertakings, which include the net proceeds of bond issuances advanced as loans, also approximate to the fair value of these financial liabilities. All other assets and liabilities are approximate to the carrying amount.
| |||||||||||
|
| |||||||||||
12 | Adjustments reconciling operating profit to operating cash flows | |||||||||||
|
|
|
|
|
| |||||||
|
|
|
| Period ended | Period ended | |||||||
|
|
|
| 30 June 2018 | 30 June 2017 | |||||||
|
|
|
| £'000 | £'000 | |||||||
|
|
|
|
|
| |||||||
| Operating profit |
|
| 20,798 | 5,022 | |||||||
| Adjustments: |
|
|
|
| |||||||
| Decrease / (increase) in other receivables |
|
| 3,317 | (6,441) | |||||||
| (Decrease) in other payables |
|
| (13,836) | (199) | |||||||
| Exchange adjustments |
|
| (3,565) | 511 | |||||||
| Amortisation of bond costs |
| (8,787) | 5,340 | ||||||||
| Fair value movements on cash flow hedges |
| 1,288 | - | ||||||||
| Reclassification of cash flow hedges to the income statement |
| 731 | 477 | ||||||||
|
|
|
|
| - | |||||||
|
|
| (22,852) | (312) | ||||||||
|
|
|
|
|
| |||||||
| Net cash (outflow) / inflow from operating activities | (54) | 4,710 | |||||||||
|
|
|
|
|
| |||||||
13 | Called up share capital |
|
| |||||||||
|
|
|
| 30 June 2018 | 31 December 2017 | 30 June 2018 | 31 December 2017 | |||||
|
|
|
| Number of shares | Number of shares | £'000 | £'000 | |||||
|
|
|
|
|
|
|
| |||||
| Authorised |
|
|
|
|
| ||||||
| Ordinary shares of £1 each (31 December 2017: £1 each) | 100,000 | 100,000 | 100 | 100 | |||||||
|
|
|
|
|
| |||||||
| Issued and fully paid |
|
|
|
| |||||||
| Ordinary shares of £1 each (31 December 2017: £1 each) | 100,000 | 100,000 | 100 | 100 | |||||||
|
|
|
|
|
| |||||||
14 | Related party transactions |
|
|
|
| |||||||
|
|
|
|
|
| |||||||
| As a wholly owned subsidiary of the ultimate parent company, GlaxoSmithKline plc, advantage has been taken of the exemption afforded by FRS 101 "Reduced Disclosure Framework" not to disclose any related party transactions within the Group. There are no other related party transactions. | |||||||||||
|
|
|
|
|
| |||||||